Key Highlights
•
A new oral form of the chemotherapy drug paclitaxel (called DHP107) was tested against the standard intravenous (IV) version for treating advanced breast cancer. This could be a major step forward, as the oral pill avoids the need for long IV infusions and may reduce common side effects like severe allergic reactions and nerve damage.
Source →
•
For lung cancer patients with specific genetic mutations (EGFR plus other tumor suppressor gene changes), adding standard chemotherapy to the targeted drug aumolertinib significantly delayed cancer progression compared to the targeted drug alone. This finding provides a new, more effective treatment strategy for a group of patients who typically don’t respond as well to standard targeted therapy.
Source →
•
Researchers discovered a new, targetable mechanism that drives cancer growth in tumors that have lost the PTEN gene, a common event in many cancers. They found that an existing FDA-approved drug, dasatinib, can block this mechanism and slow tumor growth specifically in PTEN-deficient cancers, offering a promising new use for an old drug.
Source →
•
A large European study found that lung scarring (interstitial lung disease) linked to a specific autoimmune disease (ANCA-associated vasculitis) often has a severe pattern and progresses quickly. The study suggests that the drug rituximab may help preserve lung function in these patients, highlighting the need for early diagnosis and tailored treatment.
Source →
•
A study across three large patient groups linked obesity-related changes in gut bacteria to poorer attention, identifying a specific microbial metabolite (3-HAA) that improves attention when supplemented. This reveals the gut microbiome and 3-HAA as potential new targets for treatments to improve cognitive issues, especially in people with obesity.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
